New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
16:15 EDTOMEROmeros reports Q2 EPS (53c) with items, consensus (52c)
Reports Q2 revenue $45,000, consensus $130,000. Q2 results included $2.5M, or 7c per share of non-cash expenses. The decrease in revenue, year over year, was due to a reduction of activity on NIH grant projects, which resulted in lower revenue being recognized.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
09:16 EDTOMEROn The Fly: Pre-market Movers
Subscribe for More Information
07:02 EDTOMEROmeros reports OMS721 inhibits thrombus formation in sera from aHUS patients
Subscribe for More Information
November 13, 2014
08:16 EDTOMEROmeros price target raised to $28 from $20 at Maxim
Maxim raised its price target for Omeros shares to $28 citing better than expected pricing for Omidria. The firm believes global sales of the drug could reach north of $400M by 2017 and keeps a Buy rating on Omeros.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use